Norpace CR (disopyramide phosphate) extended-release capsules USP,150 mg, packaged in a) 100-count bottles (NDC 0025-2742-31), and b) 500-count bottles (NDC 0025-2742-51), Rx only, Distributed by G.D. Searle LLC, Division of Pfizer Inc, NY, NY 10017.

FDA recall notice · announced December 16, 2015 · Pfizer

Class III FDA/FSIS Class III: use is not likely to cause adverse health consequences.

The product

Norpace CR (disopyramide phosphate) extended-release capsules USP,150 mg, packaged in a) 100-count bottles (NDC 0025-2742-31), and b) 500-count bottles (NDC 0025-2742-51), Rx only, Distributed by G.D. Searle LLC, Division of Pfizer Inc, NY, NY 10017.

Reason for recall

Failed Dissolution Specification

Notes

Distribution: Nationwide
Lot/code information: Lot #: C150065; C150064, Exp 6/16
Quantity: a) 4005 bottles, b) 104 bottles
Status: Terminated
Products in this recall event:
- Norpace CR (disopyramide phosphate) extended-release capsules USP,150 mg, packaged in a) 100-count bottles (NDC 0025-2742-31), and b) 500-count bottles (NDC 0025-2742-51), Rx only, Distributed by G.D. (D-0520-2016)

Source: U.S. Food and Drug Administration public recall data. This page reports official records and is not legal, medical, or repair advice.